PrEP for HIV and STIs Prevention
(CAMELLIA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial seeks to understand how pre-exposure prophylaxis (PrEP) can prevent HIV and STIs, focusing on black, cisgender, and transgender women at higher risk. The researchers aim to create a group of women in Alabama at risk for HIV to study factors affecting their chances of contracting HIV or other STIs and what predicts their use of PrEP. Participants will use a mobile health app to stay engaged and provide self-collected testing and surveys. Women who have had an STI in the past three months and own a smartphone may be suitable for this study. As an unphased trial, this study offers participants the chance to contribute to important research that could lead to better prevention strategies for at-risk communities.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this protocol is safe for participants?
Research has shown that PrEP (pre-exposure prophylaxis) is generally safe for reducing the risk of HIV. This treatment is easy for most people to handle, with studies indicating it effectively lowers HIV infection rates and has few side effects. Reports confirm its safety for different groups, including those at higher risk for HIV.
In previous studies, most people using PrEP did not experience serious side effects. Some common, mild side effects like nausea or headaches may occur, but they usually resolve over time. The continued use of PrEP in clinical settings suggests that users do not face major issues.
Overall, PrEP is considered a reliable and safe way to prevent HIV, especially for those more likely to get infected.12345Why are researchers excited about this trial?
Researchers are excited about the PrEP for HIV and STIs Prevention trial because it aims to refine a mobile health app called HealthMpowerment (HMP) to better engage and retain women at risk of HIV in Alabama. Unlike traditional methods that rely heavily on in-person interactions or routine medical visits, this approach uses digital technology to provide ongoing support and education. The app's ability to focus on geospatial analysis of HIV risk and self-collected testing empowers users with personalized insights and proactive health management, potentially increasing the effectiveness of PrEP usage and decreasing new infections.
What evidence suggests that this trial's treatment could be effective for preventing HIV and STIs?
Research has shown that pre-exposure prophylaxis (PrEP) is a strong method for preventing HIV, especially for those at higher risk, such as black, cisgender, and transgender women. Studies have found that taking PrEP daily can lower the chance of getting HIV from sex by about 99%. The Camellia Cohort study, which is the focus of this trial, aims to learn how women at high risk use PrEP and what factors influence its use. This research seeks to improve HIV prevention and guide future efforts. Early results from the study suggest that using technology, like mobile health apps, can help keep women involved in their PrEP care.13467
Who Is on the Research Team?
Lynn T. Matthews, MD, MPH
Principal Investigator
University of Alabama at Birmingham
Are You a Good Fit for This Trial?
This study is for cis and trans-gender women aged 18-50 living in Alabama who have had an STI recently but are currently HIV negative, gonorrhea and syphilis free, and own a private smartphone.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Enrollment and Baseline Assessment
Participants are enrolled and baseline data is collected using a mobile health app
Longitudinal Follow-up
Participants are followed longitudinally to assess factors associated with STI/HIV infection and PrEP use
Follow-up
Participants are monitored for safety and effectiveness after the main study period
What Are the Treatments Tested in This Trial?
Interventions
- Camelia Cohort
Trial Overview
The CAMELLIA Cohort study aims to understand sexual health better by tracking the use of PrEP—a medication that prevents HIV—and identifying factors linked to STI risk and HIV prevention among at-risk women.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
To better understand contextual factors among people who identify as women in Alabama that predict STI/HIV infection and PrEP use, we will refine an existing evidence-based mobile health app (HealthMpowerment or HMP) to optimally engage and retain a digital cohort of women at-risk for HIV infection (i.e. prior infection in the past 3 months with gonorrhea or syphilis). Using a sampling strategy based on geospatial analysis of HIV-risk, we will enroll and follow our factors associated with incident STI/HIV infection as well as utilization of PrEP through self-collected STI/HIV testing and survey assessments.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
Published Research Related to This Trial
Citations
CAMELLIA Cohort: A Longitudinal Study to Understand ...
The purpose of this study is to use a population-based approach to create a cohort of cis and trans-gender women at risk for future HIV acquisition to better ...
2.
healthmpowerment.org
healthmpowerment.org/wp-content/uploads/2023/05/Camellia-Cohort-Study-Summary-05.09.2023.pdfCamellia Cohort Study Summary
Pre-exposure prophylaxis (PrEP) is an important biomedical HIV prevention tool and may particularly benefit black, cis and.
Leveraging public health infrastructures to support sexual ...
Conclusion: The Camellia Cohort integrates epidemiologic methods, mHealth technology, and data science to better characterize HIV transmission ...
RePORT RePORTER - National Institutes of Health (NIH) |
Outcomes from this study will help identify gaps in reaching Southern women at highest risk for acquiring HIV and guide future intervention development. NIH ...
CAMELLIA Cohort: A longitudinal study to ... - NIH RePORTER
Outcomes from this study will help identify gaps in Ending the HIV Epidemic initiatives in reaching Southern women at highest risk for acquiring HIV and guide ...
CAMELLIA Cohort - NIH RePORTER
This novel research proposal utilizes a population-based approach to establish a geographically representative cohort of cis- and trans-gender women ('Camellia ...
PrEP for HIV and STIs Prevention (CAMELLIA Trial)
PrEP has been shown to be a safe method for reducing HIV incidence in various studies, with high rates of retention and preventive care in clinical settings.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.